Human African trypanosomiasis: Future prospects for chemotherapy

Drugs of the Future

Volumn 32, Issue 2, 2007, Pages 149-160

  D'Silva, Claudius ^a  

^a MANCHESTER METROPOLITAN UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 5 (1 METHYL 5 NITRO 2 IMIDAZOLYL) 1,3,4 THIADIAZOLE; ANTIPARASITIC AGENT; BD 289; BISPHOSPHONIC ACID DERIVATIVE; BMAP 18; BMAP 27; CATHELICIDIN; DEFENSIN; DIAMIDINE DERIVATIVE; DIMINAZENE; DIMINAZENE ACETURATE; EFLORNITHINE; GERANYLTRANSFERASE; GLUTATHIONE PEPTIDE DERIVATIVE; INORGANIC PYROPHOSPHATASE; MELARSOPROL; METRONIDAZOLE; NIFURTIMOX; PAFURAMIDINE MALEATE; PENTAMIDINE; PENTAMIDINE ISETHIONATE; PENTAMIDINE MESYLATE; POLYPEPTIDE ANTIBIOTIC AGENT; PREDNISOLONE; PROTEGIN 1; RISEDRONIC ACID; SMAP 29; SURAMIN; TRIAZINE DERIVATIVE; TRYBIZINE; UNCLASSIFIED DRUG;

AFRICA; AFRICAN TRYPANOSOMIASIS; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANAPHYLACTIC SHOCK; ANOREXIA; ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; BONE MARROW TOXICITY; BRAIN DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC TEST; DIARRHEA; DISEASE COURSE; DISULFIDE BOND; DOSAGE SCHEDULE COMPARISON; DRUG APPROVAL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG FATALITY; DRUG FORMULARY; DRUG MECHANISM; DRUG PENETRATION; DRUG STRUCTURE; DRUG SYNTHESIS; ENDEMIC DISEASE; FOLLOW UP; GENOTOXICITY; HUMAN; HYPOGLYCEMIA; HYPOTENSION; INFECTION PREVENTION; KIDNEY FAILURE; MORTALITY; MULTIPLE CYCLE TREATMENT; MUSSEL; NEUROLOGIC DISEASE; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PREVALENCE; PROPHYLAXIS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; SEIZURE; SKIN MANIFESTATION; TREATMENT DURATION; TREATMENT PLANNING; TRYPANOSOMA BRUCEI;

EID: 34247499418     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2007.032.02.1072584     Document Type: Review

References (90)

1. Dumas, M., Bouteille, B., Buguet A. (Eds.). Progress in Human African Trypanosomiasis, Sleeping Sickness. Springer-Verlag, Paris, 1999.
2. Making health research work for poor people - Human African trypanosomiasis. TDR 2005-Seventeenth programme Report-Progress 2003-2004; http://www.who.int/tdr/publications/publications/pr17.htm.
3. Fevre, E.M., Picozzi, K., Fyfe, J. et al. A burgeoning epidemic of sleeping sickness in Uganda. The Lancet 2005, 366: 745-7.
4. A testing time for tsetse eradication? New Agriculturist (online publication). http:/www.new-agri.co.uk/02-6/pov.html.
5. Workers on African trypanosomiasis unite. TDR News 2006, No. 76 (online publication). http://www.who.int/tdr/publications/tdrnews/news76/tryps. htm.
6. http://www.eanett.org/whatis/
7. Iborra, C., Danis, M., Bricaire, F. et al. A traveller returning from central Africa with fever and a skin lesion. Clin Infect Dis 1999, 28: 679-80.
8. Grau Junyent, J.M., Rozman, M., Corachán, M. et al. An unusual course of West African trypanosomiasis in a Caucasian man. Trans R Soc Trop Med Hyg 1987, 81: 931-2.
9. Buissonnière, R.F., de Boissieu, D., Tell, G. et al. Uveo-meningitis revealing a West African trypanosomiasis in a 12-year-old girl. Arch Fr Pediatr 1989, 46: 517-9.
10. Scott, J.A., Davidson, R.N., Moody, A.H. et al. Diagnosing multiple parasitic infections: Trypanosomiasis, loiasis and schistosomiasis in a single case. Scand J Infect Dis 1991, 23: 777-80.
11. Damian, M.S., Dorndorf, W., Burkardt, H. et al. Polyneuritis and myositis in Trypanosoma gambiense infection. Dtsch Med Wochenschr 1994, 119: 1690-3.
12. Otte, J.A., Nouwen, J.L., Wismans, P.J. et al. African sleeping sickness in the Netherlands. Ned Tijdschr Geneeskd 1995, 139: 2100-4.
13. Malvy, D., Djossou, F., Weill, F.X. et al. Human African trypanosomiasis from Trypanosoma brucei gambiense with inoculation chancre in a French expatriate. Med Trop (Mars) 2001, 61: 323-27.
14. Raffenot, D., Rogeaux, O., Goer, B.D. et al. Infectious mononucleosis or sleeping sickness? Ann Biol Clin (Paris) 2000, 58: 94-6.
15. Bisoffi, Z., Beltrame, A., Monteiro, G. et al. African trypanosomiasis gambiense, Italy. Emerg Infect Dis 2005, 11: 1745-7.
16. Moore, D.A., Edwards, M., Escombe, R. et al. African trypanosomiasis in travelers returning to the United Kingdom. Emerg Infect Dis 2002, 8: 74-6.
17. Jelinek, T., Bisoffi, Z., Bonazzi, L. et al. Cluster of African trypanosomiasis in travelers to Tanzanian National Park. Emerg Infect Dis 2002, 8: 634-5.
18. Ripamonti, D., Massari, M., Arici, C. et al. African sleeping sickness in tourists returning from Tanzania: The first 2 Italian cases from a small outbreak among European travellers. Clin Infect Dis 2002, 34(1): E18-22.
19. Moore, A.C., Ryan. E.T., Waldron, M.A. Case 20-2002. A 37-year-old man with fever, hepatosplenomegaly, and a cutaneous foot lesion after a trip to Africa. New Engl J Med 2002, 346: 2069-76.
20. Sinha, A., Grace, C., Kemper Alston, W. et al. African trypanosomiasis in two travellers from the United States. Clin Infect Dis 1999, 29: 840-4.
21. Ponce de Leon, S., Lisker-Melman, M., Kato-Maeda, M. et al. Trypanosoma brucei rhodesiense infection imported to Mexico from a tourist in Kenya. Clin Infect Dis 1996, 23: 847-8.
22. Stich, A., Abel, P.M., Krishna, S. Human African trypanosomiasis. BMJ 2002, 325: 203-6.
23. Greenwood, B.M., Whittle, H.C. The pathogenesis of sleeping sickness. Trans R Soc Trop Med Hyg 1980, 74: 716-25.
24. Bailey, J.W., Smith, D.H. The use of the acridine orange QBC technique in the diagnosis of African trypanosomiasis. Trans R Soc Trop Med Hyg 1992, 86: 630.
25. Steverding, D. A new initiative for the development of new diagnostic tests for human African trypanosomiasis. Kinetoplastid Biol Dis 2006, 5: 1-3.
26. Denise, H., Matthews, K., Lindegard, G. et al. Trypanosomiasis and leishmaniasis. Between the idea and the reality of control. Parasitol Today 1999, 15: 43-5.
27. Barrett, M.P., Fairlamb, A.H. The biochemical basis of arsenical-diamidine crossresistance in African trypanosomes. Parasitol Today 1999, 15: 136-40.
28. Maser, P., Luscher, A., Kaminsky, R. Drug transport and drug resistance in African trypanosomes. Drug Resist Updates 2003, 6: 281-90.
29. Zhou, W.C., Xin, Z.M., Zhang, X.P. et al. Synthesis and antiprotozoal activities of some new triazine derivatives including a new antitrypanosomal agent: SIPI-1029. Yao Xue Xue Bao 1996, 31: 823-30.
30. Atouguia, J.L.M., Kennedy, P.G.E. Neurological aspects of human African trypanosomiasis. In: Infectious Diseases of the Nervous System. Davis, L.E., Kennedy, P.G.E. (Eds.). Butterworth-Heinemann, Oxford, 2000, 321-37.
31. Burri, C., Nkunku, S., Merolle, A. et al. Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense a randomised trial. Lancet 2000, 355: 1419-25.
32. Pepin, J., Milord, F., Khonde, A. et al. Gambiense trypanosomiasis frequency of, and risk factors for failure of melarsoprol therapy. Trans R Soc Trop Med Hyg 1994, 88: 447-52.
33. Kennedy, P.G.E. Human African trypanosomiasis of the CNS: Current issues and challenges. J Clin Invest 2004, 113: 496-504.
34. Kennedy, P.G.E. Sleeping sickness - Human African trypanosomiasis. Pract Neurol 2005, 5: 260-7.
35. Pepin, J., Milord, F., Guern, C. et al. Trial of prednisolone for prevention of melarsoprol-induced encephalopathy in gambiense sleeping sickness. Lancet 1989, 1: 1246-50.
36. Van Nieuwenhove, S. Present strategies in the treatment of human African trypanosomiasis. In: Progress in Human African Trypanosomiasis, Sleeping Sickness. Dumas, M., Bouteille, B., Buguet, A. (Eds.). Springer-Verlag, Paris, 1999.
37. Prata, A. Clinical and therapeutic aspects of Chagas disease. Lancet Infect Dis 2001, 1: 92-100.
38. Pepin, J., Milord, F., Guern, C. et al. An open clinical trial of nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness in central Zaire. Ann Trop Med Parasitol 1989, 83(Suppl. 1): 111-4.
39. Van Nieuwenhove, S. Advances in sleeping sickness therapy. Ann Soc Belg Med Trop 1992, 72: 39-51.
40. Pepin, J., Milord, F., Meurice, F. et al. High-dose nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness an open trial in central Zaire. Trans R Soc Trop Med Hyg 1992, 86: 254-6.
41. Janssens, P.G., De Muynck, A. Clinical trials with "nifurtimox" in African trypanosomiasis. Ann Soc Belg Med Trop 1977, 57: 475-80.
42. Moens, F., De Wilde, M., Ngato, K. Essai de traitement au nifurtimox de la trypanosomiase humaine africane. Ann Soc Belg Med Trop 1984, 64: 37-43.
43. Stanghellini, A., Josenando, T. The situation of sleeping sickness in Angola: A calamity. Trop Med Int Health 2001, 6: 330-4.
44. Legros, D., Ollivier, G., Gastellu-Etchegorry, M. et al. Treatment of human African trypanosomiasis - Present situation and needs for research and development. Lancet Infect Dis 2002, 2: 437-40.
45. Legros, D., Evans, S., Maiso, F. et al. Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda. Trans R Soc Trop Med Hyg 1999, 93: 439-42.
46. Pepin, J., Mpia, B. Trypanosomiasis relapse after melarsoprol therapy, Democratic Republic of Congo, 1982-2001. Emerg Infect Dis 2005, 11: 921-7.
47. Pepin, J., Khonde, N. Relapses following treatment of early-stage Trypanosoma brucei gambiense sleeping sickness with a combination of pentamidine and suramin. Trans R Soc Trop Med Hyg 1966, 90: 183-6.
48. Simarro, P.P., Asumu, P.N. Gambian trypanosomiasis and synergism between melarsoprol and enflornithine: First case report. Trans R Soc Trop Med Hyg 1996, 90: 315.
49. Jennings, F.W. Combination chemotherapy of CNS trypanosomiasis. Acta Trop 1993, 54: 205-13.
50. Mpia, B., Jacques, P. Combination of efornithine and melarsoprol for melarsoprol-resistant Gambian trypanosomiasis. Trop Med Int Health 2002, 7: 775-9.
51. Pepin, J., Milford, F. The treatment of human African trypanosomiasis. Acta Parasitol 2002, 33: 1-47.
52. Clerinx, J., Taelman, H., Bogaerts, J. et al. Treatment of late stage rhodesiense trypanosomiasis using sumarin and eflornithine - Report of six cases. Trans R Soc Trop Med Hyg 1998, 92: 449-50.
53. Foulkes, J.R. Metronidazole and suramin combination in the treatment of arsenical refractory Rhodesian sleeping sickness - A case study. Trans R Soc Trop Med Hyg 1966, 90: 422.
54. Arroz, J., Djedje, M. Suramin and metronidazole in the treatment of Trypanosoma brucei rhodesiense. Trans R Soc Trop Med Hyg 1988, 82: 421.
55. Donkor, I.O., Huang, T.L., Toa, B. et al. Trypanocidal activity of conformationally restricted pentamidine congeners. J Med Chem 2003, 46: 1041-8.
56. Ansede, J.H., Anbazhagan, M., Brun, R. et al. O- Alkoxyamidine prodrugs of furamidine: In vitro transport and microsomal metabolism as indicators of in vivo efficacy in a mouse model of Trypanosoma brucei rhodesiense. Infect J Med Chem 2004, 47: 4335-8.
57. Boykin, D.W., Kumar, A., Bender, B.C. et al. Anti-Pneumocystis activity of bis-amidoximes and bis-O-alkylamidoximes prodrugs. Bioorg Med Chem Lett 1996, 6: 3017-20.
58. Immtech completes enrollment in phase III pivotal trial of pafuramidine for African sleeping sickness. Immtech Pharmaceuticals, Inc. Press Release, January 30, 2007.
59. Zhou, W., Xin, Z., Zhang, X. (Shanghai Institute of Pharmaceutical Industry). Triazines derivatives and preparing process thereof. CN 1096514.
60. Kaminsky, R., Brun, R. In vitro and in vivo activities of trybizine hydrochloride against various pathogenic trypanosome species. Antimicrob Agents Chemother 1998, 42: 2858-62.
61. Bacchi, C.J., Brun, R., Croft, S.L. et al. In vivo trypanocidal activities of new S-adenosylmethionine decarboxylase inhibitors. Antimicrob Agents Chemother 1996, 40: 1448-53.
62. Bacchi, C.J., Vargas, M., Rahendi, D. et al. Antitrypanosomal activity of a new triazine derivative, SIPI-1029, in vitro and in model infections. Antimicrob Agents Chemother 1998, 42: 2718-21.
63. Poli, P., deMello, M.A., Buschini, A. et al. Cytotoxic and genotoxic effects of megazol, an anti-Chagas' disease drug assessed by different short-term tests. Biochem Pharmacol 2002, 64: 1617-27.
64. Steward, M.L., Bueno, G.T., Balioni, A. et al. Trypanocidal activity of melamine-based nitrohetercycles. Antimicrob Agents Chemother 2004, 48: 1733-8.
65. Fries, D.S., Fairlamb, A.H. Antiprotozoal agents. In: Burger's Medicinal Chemistry and Drug Discovery: Chemotherapeutic Agents (6th Ed.). Abraham, D.J. (Ed.). John Wiley & Sons, 2003, 1033-87.
66. Keiser, J., Stich, A., Burri, C. New drugs for the treatment of human African trypanosomiasis: Research and development. Trends Parasitol 2001, 17: 42-9.
67. Burchmore, R.J.S., Ogbunude, P.O.J., Enanga, B. et al. Chemotherapy of human African trypanosomiasis. Curr Pharm Des 2002, 8: 256-67.
68. Schmidt, A., Krauth-Siegel, R.L. Enzymes of the trypanothione metabolism as targets for antitrypanosomal drug development. Curr Top Med Chem 2002, 2: 1239-59.
69. Augustyns, K., Amssoms, K., Yamani, A. Trypanothione as a target in the design of antitrypanosomal and antileishmanial agents. Curr Pharm Des 2001, 7: 1117-41.
70. Barrett, M.P., Gilbert, I.H. Perspectives for new drugs against trypanosomiasis and leishmaniasis. Curr Top Med Chem 2002, 2: 471-82.
71. D'Silva, C., Daunes, S. The therapeutic potential of inhibitors of the trypanothione cycle. Expert Opin Invest Drugs 2002, 11: 217-31.
72. Linares, E.G., Ravaschino, E.L., Rodhquez, J.D. et al. Progresses in the field of drug design to combat tropical protozoan parasitic diseases. Curr Med Chem 2006, 13: 335-60.
73. Fairlamb, A.H. Chemotheraphy of human African trypanosomiasis: Current and future prospects. Trends Parasitol 2003, 19: 488-94.
74. Hamilton, C.J., Saravanamuthu, A., Fairlamb, A.H. et al. Benzofuranyl 3,5-bis-polyamine derivatives as time-dependent inhibitors of trypanothione reductase. Bioorg Med Chem Lett 2003, 11: 3683-93.
75. Hamilton, C.J., Saravanamuthu, A., Poupat, C. et al. Time-dependent inhibitors of trypanothione reductase: Analogues of the spermidine alkaloid lunarine and related natural products. Bioorg Med Chem Lett 2006, 14: 2266-78.
76. Lee, B., Bauer, H., Melchers, J. et al. Irreversible inactivation of trypanothione reductase by unsaturated Mannich bases. A divinyl ketone as key intermediate. J Med Chem 2005, 48: 7400-10.
77. Montalvetti, A., Fernandez, A., Sanders, J.M. et al. Farnesyl pyrophosphate synthase is an essential enzyme in Trypanosoma brucei. In vitro RNA interference and in vivo inhibition studies. J Biol Chem 2003, 278: 17075-83.
78. Martin, M.B., Grimley, J.S., Lewis, J.C. et al. Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: A potential route to chemotherapy. J Med Chem 2001, 44: 909-16.
79. Martin, M.B., Saunders, J.M., Kendrick, K. et al. Activity of bisphosphonates against Trypanosoma brucei rhodesiense. J Med Chem 2002, 45: 2904-14.
80. Kotsikorou, E., Song, Y., Chan, J.M.W. et al. Bisphosphonate inhibition of the exopolyphosphatase activity of the Trypanosoma brucei soluble vacuolar pyrophosphatase. J Med Chem 2005, 48: 6128-39.
81. Lehrer, R.I., Ganz, T. Antimicrobial peptides in mammalian and insect host defence. Curr Opin Immunol 1999, 11: 23-7.
82. Lehrer, R.I.., Barton, A., Daher, K.A. et al. Interaction of human defensins with Escherichia coli: Mechanism of bactericidal activity. J Clin Invest 1989, 84: 553-61.
83. McGwire, B.S., Olson, B.S., Tack, B.F. et al. Killing of African trypanosomes by antimicrobial peptides. J Infect Dis 2003, 188: 146-52.
84. Romestand, B., Molina, F., Richard, V. et al. Key role of the loop connecting the two beta strands of mussel defensin in its antimicrobial activity. Eur J Biochem 2003, 270: 1-9.
85. Roch, P., Beschin, A., Bernard, E. Antiprotozoan and antiviral activities of non-cytotoxic truncated and variant analogues of mussel defensin. Evid Based Complement Alternat Med 2004, 1: 167-74.
86. Haines, L.R., Hancock, R.E., Pearson, T.W. Cationic antimicrobial peptide killing of African trypanosomes and Sodalis glossinidus, a bacterial symbiont of the insect vector of sleeping sickness. Vector Borne Zoonotic Dis 2003, 3: 175-86.
87. Teresa, M.F., Santosh, M. Production of an anti-trypanosomal peptide in potato for treatment of African sleeping sickness. Plant Biology 2005 (July 16-20, Seattle) 2005, Abst 1079.
88. Daunes, S., D'Silva, C., Kendrick, H. et al. A QSAR study on the contribution of log P and Es to the in vitro antiprotozoal activity of glutathione derivatives. J Med Chem 2001, 44: 2976-83.
89. Daunes, S., D'Silva, C. Glutathione derivatives active against T. b. rhodesiense and T. b. brucei in vitro. Antimicrob Agents Chemother 2002, 46: 434-7.
90. D'Silva, C., Daunes, S., Tomas, A. et al. The mode of action of glutathione peptides as antiprotozoal agents. World Conf Magic Bullets (Sept 9-11, Nurnberg) 2004, Abst 113.